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Purpose: This study was conducted to analyze the efficacy of photoselective vapor-
ization of the prostate (PVP) with the use of a 980 nm diode laser for benign prostatic 
hyperplasia (BPH) according to postoperative period. 
Materials and Methods: Data were collected from 96 patients who were diagnosed with 
BPH and who underwent PVP with the 980 nm K2 diode laser. Postoperative parame-
ters, including International Prostate Symptom Score (IPSS), quality of life (QoL) score, 
maximum urinary flow rate (Qmax), and post-void residual volume (PVR), were as-
sessed and compared with preoperative baseline values.
Results: The mean prostate volume was 45.3±15.6 g, the mean operative time (lasing 
time) was 22.9±18.3 minutes, the total amount of energy was 126±84 kJ, and the Foley 
catheter maintenance period after PVP was 24.8±5.6 hours. At 1 month, significant 
improvements were noted in IPSS (11.7±6.6), QoL score (2.3±1.1), Qmax (12.7±6.1
ml/sec), and PVR (41.9±30.5 ml). After 3 months, all follow-up parameters showed sig-
nificant improvements that were sustained throughout a period of 6 months after PVP.
Conclusions: PVP using a K2 diode laser is a minimally invasive and effective surgical 
method for improvement of BPH and is associated with minimal morbidity.
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INTRODUCTION 
The prevalence of benign prostatic hyperplasia (BPH) has 
shown a progressive increase, owing much to an increase 
in the elderly population, advancement in diagnostic meth-
ods, economic growth, and desire for a better quality of life 
[1]. The initial treatment of BPH is mostly through medi-
cations, but some patients who show no improvements in 
their conditions with medication choose surgical treat-
ment. Transurethral resection of the prostate (TURP) is 
the most standard surgical procedure performed for BPH 
to date [2]. However, complications such as bleeding, retro-
grade ejaculation, and transurethral resection (TUR) syn-
drome can occur after TURP [3-6]. Therefore, various la-
sers have been introduced as alternatives to TURP to mini-
mize such complications. Recent photoselective vapor-
ization of the prostate (PVP) procedures have used high-en-
ergy 80 W potassium-titanyl-phosphate (KTP) lasers and 
120 W lithium-triborate lasers. 
Numerous studies have shown that PVP shows surgical 
outcomes similar to those of TURP, but reduces the hospi-
tal stay and catheterization time dramatically and further 
reduces bleeding, thereby decreasing possible complica-
tions [7-9]. A recently introduced diode laser system oper-
ates on a wavelength of 980 nm. Because this wavelength 
offers a high simultaneous absorption in water and hemo-
globin, it is postulated to combine high tissue ablative prop-
erties with good hemostasis. The aim of this study was to 
clinically evaluate the usefulness of the high-power 980 nm 
diode laser in the treatment of BPH. Korean J Urol 2011;52:752-756
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TABLE 1. Characteristics of the patients
Mean±SD Range
Age (yr)
PSS
QoL score
Qmax
PVR
PSA
Prostate volume (g)
73.5±6.4
19.3±8.3
  4.2±1.1
  8.5±5.7
    99.1±138.9
  3.5±1.8
  45.3±15.6
55-81
  0-35
1-6
  1.5-25.0
    0-400
1-5
21-90
IPSS: International Prostate Symptom Score, QoL: quality of 
life, Qmax: maximum urinary flow rate, PVR: post-void residual 
volume, PSA: prostate-specific antigen
TABLE 2. Perioperative outcomes
 Mean±SD Range
Operation time (lasing time, min)
Applied energy (kJ)
Catheterization time (hr)
  22.9±18.3
126±84
24.8±5.6
10-60
    5-250
20-48
MATERIALS AND METHODS 
A retrospective study was performed from March 2010 to 
December 2010. We treated 96 patients diagnosed with 
bladder outlet obstruction secondary to BPH. In all cases, 
pharmacological treatment had been tried, with minimal 
or null response. 
Patients were evaluated by means of anamnesis (the 
symptoms being evaluated through the International 
Prostate Symptom Score (IPSS), the quality of life (QoL) 
score, physical examination including digital rectal exami-
nation (DRE), prostate-specific antigen (PSA), transrectal 
ultrasonography, and uroflowmetry. Inclusion criteria 
were moderate to severe urinary symptoms, as determined 
by IPSS (score≥8) and Qmax of less than 15 ml/s with or 
without post-void residual volume (PVR). Exclusion cri-
teria were urethral stricture, previous prostatic surgery, 
prostate cancer, and obvious manifested neurogenic blad-
der dysfunction. 
Spinal anesthesia was used in all cases, and surgery was 
performed by a single surgeon. Prostate vaporization was 
carried out with a diode laser at 980 nm (K2 diode laser sys-
tem, Huentek, Seoul, Korea) delivering 120 W of maximum 
output power with a 600 nm side-fire fiber endowed within 
a spot of 1 mm in diameter. In all cases, saline solution was 
used for irrigation through a 23 F cystoscope. Vaporization 
was started at the bladder neck in a clockwise manner, pull-
ing the resectoscope further out and rotating the laser fiber 
simultaneously with the power set at 80 to 120 W. All pros-
tate tissue causing obstruction was removed until a fine 
surgical cavity was formed, as in TURP. In all cases, an 18 
F three-way catheter was placed despite obtaining clear 
urine or minimal hematuria. A urethral catheter was 
placed after the operation and was removed the next day, 
taking into consideration the degree of hematuria. 
Postoperative Qmax, PVR, and IPSS with QoL score 
were obtained at 1, 3, and 6 months after surgery. 
Operation time, applied energy, and duration of catheter-
ization were obtained. For statistical analysis, we used 
SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA). Postoperat-
ive Qmax, PVR, IPSS, and QoL score were compared with 
preoperative values by using the Student t-test (paired); 
p-values of less than 0.05 were defined as statistically 
significant. 
RESULTS 
A total of 96 patients met the inclusion criteria. The pa-
tients’ mean age was 73.5±6.4 years (range, 55 to 81 years), 
and the mean follow-up period was 7.2 months (range, 6 to 
9 months). Preoperative parameters were as follows: IPSS, 
19.3±8.3; QoL, 4.2±1.1; Qmax, 8.5±5.7 ml/s; PVR, 99.1± 
138.9 ml; PSA, 3.5±1.8 ng/ml; and prostate volume, 45.3± 
15.6 g (Table 1). 
Mean operation time (lasing time) was 22.9±18.3 mi-
nutes, and mean applied energy was 126±84 kJ. Mean 
catheterization duration was 24.8±5.6 hours (Table 2). One 
month after surgery, subjective and objective follow-up pa-
rameters were assessed and statistical analysis was 
performed. Compared with the preoperative data, statisti-
cally significant improvements were observed in total IPSS 
(11.7±6.6, p＜0.05), QoL score (2.3±1.1, p＜0.05), Qmax 
(12.8±6.1, p＜0.05), and PVR (41.9±30.5, p＜0.05). 
Three months after the operation, all parameters were 
reassessed, and the statistical analysis was performed 
again. Compared with the preoperative data, significant 
improvements were observed in total IPSS (8.2± 5.4, p＜ 
0.05), the QoL score (1.8±0.8, p＜0.05), Qmax (15.1±5.4, 
p＜0.05), and PVR (34.8±31.2, p＜0.05). All postoperative 
follow-up parameters were assessed again at 6 months af-
ter surgery. The 6 month total IPSS was 7.4±2.1, the QoL 
score was 1.4±0.6, Qmax was 16.7±4.91 ml/s, and PVR was 
23.0±23.4 ml. All of the above 1, 3, and 6 month postopera-
tive values were statistically significant when compared 
with baseline values and were sustained throughout the 
follow-up period (Fig. 1). 
The only major postoperative complication in our study 
was mild dysuria (n=16, 16.7%), which improved with con-
servative care. There were no complications such as de-
layed hematuria or obstructive retention with blood clot. 
DISCUSSION 
Although TUR of the prostate is considered to be the gold 
standard of care in the treatment of BPH [2], its perioper-
ative morbidity (hemorrhage, urethral stenosis, reabsorp-
tion syndrome, and catheterization times) has encouraged 
the search for alternatives than can reduce complications 
and offer at least similar clinical results [3-6]. In an attempt 
to minimize the morbidity of TURP, alternative techniques 
for prostate ablation are being developed. Korean J Urol 2011;52:752-756
754 Yang et al
FIG. 1. Changes in preoperative and postoperative International 
Prostate Symptom Score (IPSS), quality of life (QoL) score, 
post-void residual volume and score (PVR), maximum urinary 
flow rate (Qmax). 
FIG. 2. Absorption characteristics of various wavelengths in two 
absorption media for potassium-titanyl-phosphate (KTP), hol-
mium:yttrium-aluminium-garnet (Ho:YAG), neodymium:YAG 
(Nd:YAG), and diode lasers.
Holmium laser enucleation of the prostate provides func-
tional outcomes comparable to those of TURP and open 
prostatectomy [5,6]. However, a steep learning curve re-
quiring 30 to 50 procedures and a longer operation time has 
limited widespread use of the procedure [6,7]. The applica-
tion of the KTP laser (532 nm wavelength) allows good he-
mostasis owing to its high affinity for hemoglobin as well 
as prostate vaporization. However, the operation time of 
KTP-laser prostatectomy is rather long because tissue va-
porization is time-consuming. Nevertheless, given that the 
technique has a minor learning curve, its low morbidity and 
the published good medium-term results have spread its 
use [7,10-16]. 
Seitz et al reported preliminary data from a study based 
on the utilization of a diode laser of 1,470 nm at 50 W of pow-
er [17], obtaining some promising results in patients with 
BPH. However, the combination of good absorption for both 
water and hemoglobin make the diode laser at 980 nm a 
more attractive option in the treatment of BPH by means 
of vaporization of the prostate tissue. A diode laser working 
on a wavelength of 980 nm was recently introduced to over-
come the described problems of the established laser 
devices. Because this wavelength offers the highest simul-
taneous absorption in water and hemoglobin, it is postu-
lated to combine high tissue ablation capacity and good he-
mostasis (Fig. 2). Further advantages of the diode laser 
over KTP and Ho:YAG laser devices include a significantly 
lower energy consumption and the absence of a required 
high-voltage connection, which improves mobility of the la-
ser generator. Unlike other lasers, the speed of vapor-
ization with the diode laser at 980 nm does not seem to de-
pend on whether the tissue is mucosa or fibromuscular 
stroma. Regarding its hemostatic properties, it is consid-
ered to be equivalent to KTP. Using 120 W of output power, 
the depth of the coagulation was similar to that obtained 
by monopolar TUR [18]. 
Erol et al reported that in a trial of diode laser PVP with 
47 patients, the IPSS decreased from a preoperative value 
of 21.9 to 4.9 after 6 months and Qmax increased from 8.9 
ml/s to 18.3 ml/s [19]. In the present study with diode laser 
PVP, the IPSS changed from a preoperative value of 19.3 
to 11.7, 8.2, and 7.4 at 1, 3, and 6 months after surgery, re-
spectively, and Qmax changed from 8.5 ml/s preoperatively 
to 12.8, 15.1, and 16.7 ml/s after 1, 3, and 6 months, 
respectively. Compared with the reported results for the 
use of a diode laser by Erol et al, the decrease in IPSS and 
increase in Qmax were similar in this study [19]. 
In a single nonrandomized clinical series comparing the 
diode laser treatment at 980 nm with other lasers, compli-
cation rates were low and the authors reported low or no 
perioperative bleeding [20]. However, as a result of the in-
creased tissue necrosis induced by the diode laser com-
pared with the other laser, irritative symptoms as 
short-term complications such as prolonged dysuria or 
transient urge incontinence occurred more often in the di-
ode laser group. In a human cadaver model, Seitz et al dem-
onstrated that the coagulation depth could reach beyond 
7 mm in the diode laser at 980 nm. Although diode laser 
prostatectomy could ablate the prostatic tissues immedi-
ately, the deeper coagulated tissues could escape vapor-
ization, which led to remaining necrotic tissues [21]. This 
result explains the higher irritative events after diode laser 
prostatectomy. In our study, immediately after the proce-
dure, 16 patients (16%) experienced mild dysuria, which 
resolved within 2 weeks without any specific treatment. 
According to Seitz et al, there was no report of impotence 
in the 1 year follow-up observation of the group subjected 
to diode laser PVP [17]. Although completion of the 
International Index of Erectile Function (IIEF) was en-
ticed in the present study, there were difficulties in evalua-
tion because most of the patients failed to fill in the Korean J Urol 2011;52:752-756
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questionnaires. Although no patients voluntarily com-
plained of impotency, it is difficult to objectively compare 
these results with the results of other existing research be-
cause accurate assessment of the extent of erectile function 
before the surgery could not be made. Assertive and specific 
investigation is deemed to be necessary in future follow-up 
examinations.
Although Te et al reported that PVP displays a lower ex-
tent of retrograde ejaculation in comparison to TURP [7], 
Erol et al reported the frequency as 31.7% in their study 
on diode laser PVP [19]. In the present study, none of the 
outpatients voluntarily complained of retrograde ejacula-
tion. However, this result was based only on the complaints 
of the patients. We suspect that the number of patients ex-
periencing retrograde ejaculation would be substantially 
higher, and more assertive and specific investigation of 
this will be considered in the future. Accordingly, it is diffi-
cult to objectively compare the retrograde ejaculation data 
obtained in the present study with those of other studies, 
and continuous outpatient observation is deemed to be nec-
essary in the future.
This research has a weakness in that, as an early stage 
of research, the period of outpatient follow-up was short. 
In addition, consideration of the interpretation of the re-
sults is necessary for patients with risk factors (old age, 
high blood pressure, diabetes, and stroke). Although the 
presence of long-term complications such as urethral stric-
ture and bladder neck contracture were not reported in this 
research, we suggest that continuous, long-term ob-
servation is needed in the future.
This study is significant as the first report in Korea to an-
alyze the initial results of high-output 980 nm diode laser 
vaporization of the prostate, which did not differ sig-
nificantly from the results of studies of high-output diode 
laser vaporization published overseas to date. Long-term 
follow-up observation of a larger number of patients should 
be carried out to confirm the favorable short-term results 
reported in this study. 
CONCLUSIONS
In our current study, high-power diode laser vaporization 
of the prostate provided significant improvements in IPSS, 
Qmax, QoL, and PVR. Moreover, the complication rate was 
relatively minimal. According to our experience, it is a safe 
procedure that is easy to learn. Therefore, the outcome of 
the current study is encouraging. A longer period of data 
observation of a larger population and of postoperative 
complications should be evaluated next. 
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